Rare Partners is a non profit company devoted to the development of new therapies and diagnostics in the field of rare diseases.
Sirolimus has been granted Orphan Drug Designation for the treatment of sickle cell disease also in USA
The European Commission grants Orphan Drug Designation to Neupharma for the use of Teicoplanin in Cystic Fibrosis, a program developed in collaboration with Rare Partners
